A5066341215- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Advancements in Semiconductor Devices and Circuit Design
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Toxin Mechanisms and Immunotoxins
- Intraperitoneal and Appendiceal Malignancies
- Chronic Lymphocytic Leukemia Research
- Cytokine Signaling Pathways and Interactions
- Chronic Myeloid Leukemia Treatments
- Appendicitis Diagnosis and Management
- Endometrial and Cervical Cancer Treatments
Tianjin Medical University Cancer Institute and Hospital
2022-2025
Importance The efficacy of niraparib maintenance therapy with an individualized starting dose (ISD) warrants further investigation in a broad population newly diagnosed advanced ovarian cancer (aOC), including patients without postoperative residual disease. Objective To evaluate the and safety ISD aOC (R0 resection permitted). Design, Setting, Participants This multicenter, randomized, double-blind, placebo-controlled, phase 3 study was conducted China enrolled 384 who received primary or...
Abstract Purpose: In patients with platinum-sensitive relapsed (PSR) ovarian cancer, olaparib maintenance monotherapy significantly improves progression-free survival (PFS) versus placebo. However, evidence in the Asian population is lacking. This first study to evaluate efficacy and tolerability exclusively PSR cancer. Patients Methods: Considering limited placebo effect significant clinical benefit of previous trials, rapid approval China, this phase III was designed as an open-label,...
Abstract Introduction The survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) has been well defined at the time interval cytoreductive surgery, but role HIPEC remains uncertain for patients with newly diagnosed advanced ovarian cancer in upfront setting. present study aimed to report updated long‐term outcomes after 5 years follow‐up from our previous multicenter retrospective cohort compare primary surgery (PCS) plus PCS alone among women stage III epithelial cancer....
<h3>Introduction/Background</h3> Maintenance therapy, particularly with Poly-ADP-ribose polymerase (PARP) inhibitors, is recommended to extend platinum-related benefits in ovarian cancer (OC). Senaparib, a potent and selective PARP inhibitor, was investigated the FLAMES phase 3 trial confirm its efficacy safety as first-line (1L) maintenance therapy for Chinese patients newly diagnosed advanced OC. <h3>Methodology</h3> In this double-blind, placebo-controlled trial, 404 eligible FIGO stage...
5619 Background: Antiangiogenic therapy plus immunotherapy significantly improved PFS and OS as compared to chemotherapy among pts with previously treated advanced EMC per KEYNOTE-775 study. However, no combination immunotherapies are currently approved for in China. Fruquintinib (F, a highly selective VEGFR inhibitor) sintilimab (S, an anti-PD-1 monoclonal antibody) showed encouraging antitumor activity multiple solid tumors. Here, we reported the results of F S pMMR status from open-label,...
<div>AbstractPurpose:<p>In patients with platinum-sensitive relapsed (PSR) ovarian cancer, olaparib maintenance monotherapy significantly improves progression-free survival (PFS) versus placebo. However, evidence in the Asian population is lacking. This first study to evaluate efficacy and tolerability exclusively PSR cancer.</p>Patients Methods:<p>Considering limited placebo effect significant clinical benefit of previous trials, rapid approval China, this phase III...
<div>AbstractPurpose:<p>In patients with platinum-sensitive relapsed (PSR) ovarian cancer, olaparib maintenance monotherapy significantly improves progression-free survival (PFS) versus placebo. However, evidence in the Asian population is lacking. This first study to evaluate efficacy and tolerability exclusively PSR cancer.</p>Patients Methods:<p>Considering limited placebo effect significant clinical benefit of previous trials, rapid approval China, this phase III...
<h3>Introduction/Background</h3> Ovarian cancer (OC) is the most lethal gynecologic cancers. The first-line (1L) treatment of newly diagnosed advanced OC surgery and platinum-based chemotherapy, up to 85% patients (pts) may experience a recurrence. Poly ADP-ribose polymers (PARP) inhibitors are recommended as maintenance therapy prolong benefit platinum. Senaparib (IMP4297) novel, high potency PARP inhibitor. phase 3 study FLAMES confirm efficacy safety 1L in Chinese pts with OC....
<h3>Introduction</h3> FLAMES is a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate efficacy and safety of senaparib as first line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (OC). <h3>Methods</h3> Chinese diagnosed, FIGO stage III-IV, high-grade serous or endometrioid OC who had achieved complete response (CR) partial (PR) 1L platinum-based chemotherapy were randomized (2:1) receive placebo. Primary endpoint was progression-free...